Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 673

1.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, R├╝cklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
2.

Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

Aapro MS, Forbes JF.

Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

PMID:
14535530
3.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID:
17492927
4.
5.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
6.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
7.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
8.
9.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
10.

Focus on anastrozole and breast cancer.

Mokbel K.

Curr Med Res Opin. 2003;19(8):683-8. Review.

PMID:
14687437
11.

Never too late: reducing late breast cancer relapse risk.

Harbeck N.

Curr Med Res Opin. 2008 Dec;24(12):3295-305. doi: 10.1185/03007990802470639 . Review.

PMID:
18954499
12.
13.

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

Wardley AM.

Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.

PMID:
19096768
14.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

Dodwell D, Williamson D.

Cancer Treat Rev. 2008 Apr;34(2):137-44. Epub 2007 Nov 14. Review.

PMID:
18006236
15.

Overcoming recurrence risk: extended adjuvant endocrine therapy.

Cianfrocca M.

Clin Breast Cancer. 2008 Dec;8(6):493-500. doi: 10.3816/CBC.2008.n.059. Review.

PMID:
19073503
16.
17.

Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.

Nabholtz JM.

Oncology. 2006;70(1):1-12. Epub 2006 Jan 26. Review.

PMID:
16439860
18.

Anastrozole for breast cancer: recent advances and ongoing challenges.

Buzdar AU.

Expert Rev Anticancer Ther. 2006 Jun;6(6):839-48. Review.

PMID:
16761927
19.
20.

Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.

Koeberle D, Thuerlimann B.

Expert Rev Anticancer Ther. 2006 Jan;6(1):5-10. Review.

PMID:
16375638

Supplemental Content

Support Center